Abstract
The pharmacokinetics of propafenone and 5-OH-propafenone and their relationship with the antiarrhythmic action and side effects have been studied in 10 patients with stable, frequent, premature ventricular beats (224-928 premature ventricular complexes/h). Observations were made after a single dose of propafenone 300 mg p.o., and after 1 and 3 months (only 5 out of 10 patients) of therapy with 300 mg t.d.s. After 1 month of treatment the plasma elimination half-life of propafenone (6.7 h) was almost twice as long as after a single dose (3.5 h), and the area under the plasma propafenone concentration-time curve (7620 ng.ml-1.h) was significantly larger than after single dose (3522 ng.ml-1.h); this was also true for the metabolite. The ratio of the AUCs of 5-OH-propafenone and propafenone decreased from the single dose (0.63) to 1 month (0.32). These variables remained stable up to 3 months. Eight patients had greater than or equal to 75% reduction of premature ventricular complexes after 3 days of therapy, and in 7 they were completely suppressed; the response was maintained over 1 to 3 months. Side effects were minor and in no case had the drug to be withdrawn or the dose reduced. Thus, the kinetics of propafenone were time-dep...Continue Reading
References
Jan 22, 1988·Journal of Chromatography·R LatiniE Benfenati
May 1, 1986·The American Journal of Cardiology·T WangD M Roden
Jun 1, 1985·The American Journal of Cardiology·H A DinhJ A Franciosa
Feb 1, 1986·Mayo Clinic Proceedings·S C HammillD R Holmes
Jun 1, 1985·Clinical Pharmacology and Therapeutics·R E KatesR A Winkle
Nov 1, 1981·Journal of Cardiovascular Pharmacology·F LeddaA Mugelli
Nov 14, 1984·The American Journal of Cardiology·P CoumelP Assayag
Dec 1, 1983·The American Journal of Cardiology·S J ConnollyR A Winkle
Jan 1, 1984·The American Journal of Cardiology·D M SalernoM Hodges
Jul 1, 1984·Journal of the American College of Cardiology·P J Podrid, B Lown
Nov 1, 1984·The American Journal of Cardiology·F NaccarellaE Ambrosioni
Nov 14, 1984·The American Journal of Cardiology·G BreithardtL Seipel
Nov 14, 1984·The American Journal of Cardiology·J J HegerE N Prystowsky
Nov 14, 1984·The American Journal of Cardiology·L A SiddowayR L Woosley
Jan 1, 1983·Life Sciences·R M LevyY Hosobuchi
Jan 1, 1984·European Journal of Drug Metabolism and Pharmacokinetics·H G HegeH Lietz
Aug 1, 1984·Clinical Pharmacology and Therapeutics·S ConnollyR E Kates
Sep 1, 1983·Circulation·S J ConnollyR A Winkle
Feb 1, 1982·Computer Programs in Biomedicine·M Rocchetti, M Recchia
Citations
Jan 1, 1992·European Journal of Clinical Pharmacology·R LatiniJ M Castel
Feb 1, 1990·Cardiovascular Drugs and Therapy·A CapucciB Magnani
Jan 1, 1990·European Journal of Clinical Pharmacology·S VozehF Follath
Feb 1, 1989·American Heart Journal·R LatiniP Zardini
Nov 1, 1992·Journal of Pharmaceutical Sciences·G R TonnJ E Axelson
May 5, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Graham LappinColin Garner
Dec 5, 1989·The American Journal of Cardiology·P Jaillon, M Drici
May 1, 1991·The American Journal of Cardiology·W E HaefeliF Follath
Aug 1, 1992·American Heart Journal·A VincentiP Giani
Dec 14, 2002·The American Journal of Cardiology·Thomas MeinertzUNKNOWN ERAFT Investigators
Dec 2, 1998·British Journal of Clinical Pharmacology·G LiU Klotz
Feb 22, 1990·The New England Journal of Medicine·C Funck-BrentanoD M Roden